慢性乙型肝炎患者32例的肿瘤标志物检测的临床意义
|
摘要
目的分析慢性乙型肝炎患者的肿瘤标志物检测的临床意义。方法选取本院2017年9月至2018年9月接收的32例慢性乙型肝炎患者,对慢性乙型肝炎的相关肿瘤标志物进行检测,分别为β2-微球蛋白、铁蛋白、癌胚抗原、甲胎蛋白四种。结果通过分析β2-微球蛋白(β2-MC)、铁蛋白(SF)、癌胚抗原(CEA)、甲胎蛋白(AFP)检测值发现,患者的病情随着检测值的升高而加重,肝癌和肝硬变的检测值明显高于慢性肝炎的检测值,差异有统计学意义(P<0.05)。结论慢性乙型肝炎患者的肝脏病情随着肿瘤标志物的检测值升高而加重,可以侧面反映出患者的肝脏病情变化程度,研究中发现对慢性乙型肝炎的肿瘤标志物进行联合检查的原发性肝癌检测阳性率要高于单项检测,具有更高的临床使用价值。
Objective To analyze the clinical significance of detection of tumor markers in patients with chronic hepatitis B.Methods Thirty-two patients with chronic hepatitis B who were received during the period from September 2017 to September2018 were enrolled in this study. The tumor markers related to chronic hepatitis B were detected as β2-microglobulin, ferritin,carcinoembryonic antigen and alpha-fetoprotein four kinds. Results By analyzing the detection values of β2-microglobulin(β2-MC),ferritin(SF), carcinoembryonic antigen(CEA), and alpha-fetoprotein(AFP), it was found that the patient's condition aggravated with the increase of the detected value. The detection value of liver cancer and cirrhosis was significantly higher than that of chronic hepatitis,and the difference was statistically significant(P<0.05). Conclusion The liver condition of patients with chronic hepatitis B increased with the detection of tumor markers. Aggravation can reflect the degree of liver disease changes in patients. The positive rate of primary liver cancer detected by combined detection of tumor markers of chronic hepatitis B is higher than that of single test, which has higher clinical value.
Objective To analyze the clinical significance of detection of tumor markers in patients with chronic hepatitis B.Methods Thirty-two patients with chronic hepatitis B who were received during the period from September 2017 to September2018 were enrolled in this study. The tumor markers related to chronic hepatitis B were detected as β2-microglobulin, ferritin,carcinoembryonic antigen and alpha-fetoprotein four kinds. Results By analyzing the detection values of β2-microglobulin(β2-MC),ferritin(SF), carcinoembryonic antigen(CEA), and alpha-fetoprotein(AFP), it was found that the patient's condition aggravated with the increase of the detected value. The detection value of liver cancer and cirrhosis was significantly higher than that of chronic hepatitis,and the difference was statistically significant(P<0.05). Conclusion The liver condition of patients with chronic hepatitis B increased with the detection of tumor markers. Aggravation can reflect the degree of liver disease changes in patients. The positive rate of primary liver cancer detected by combined detection of tumor markers of chronic hepatitis B is higher than that of single test, which has higher clinical value.
引文
[1]韦通建.慢性乙型病毒性肝炎抗病毒治疗研究新进展[J].辽宁医学杂志,2015,29(6):318-320.
[2]庄辉.再论提高我国乙型肝炎治疗的可及性[J].肝脏,2016,24(6):401-402
[3]梁伟清.对乙肝表面抗原进行定量检测方法的研究[J].当代医药论丛,2018,16(6):49-50.
[4]吴丽萍.肿瘤标志物应用的注意事项[J].世界最新医学信息文摘,2015,15(35):105.
[5]耿亚军,赵鹏慧,梁威,等.抗病毒治疗对乙型肝炎病毒相关性原发性肝癌根治性术后肿瘤复发的影响[J].河北医学,2017,23(3):463-466.
[6]许侨东,颜永聪,黄拼搏,等.乙型肝炎病毒X蛋白在肝细胞癌中的病理作用及相关分子机制[J].实用医学杂志,2016,32(20):3448-3450.
[7]刘颖,朱以军,王月.金华地区慢性乙型肝炎患者HBV基因型及耐药基因位点突变类型分析[J].浙江医学,2017,39(14):1158-1161.
[8]郑积才,陈和敏.乙肝疫苗联合乙肝免疫球蛋白阻断乙肝母婴垂直传播的疗效及影响因素研究[J].中国全科医学,2017,20(S1):102-104.
[9]周其锋.淋巴瘤免疫化疗须防HBV再激活-《中国淋巴瘤合并HBV感染患者管理的专家共识》解读[J].医师在线,2017,7(25):23-24.
[10]石跃,朱丽影,于雷,等.HBV感染产妇应用替诺福韦酯期间哺乳婴儿安全性观察[J].中国肝脏病杂志(电子版),2018,10(2):43-48.
[11]朱复生,丁明霞,王明杰.乙肝疫苗联合乙肝免疫球蛋白阻断乙肝病毒垂直传播失败的相关危险因素分析[J].继续医学教育,2018,32(10):119-122.
[12]Hombrink P,Hassan C,Kester MG,et al.Identification of Biologica Relevant Minor Histocompatibility Antigens within the B-lymphocyteDerived HLA-Ligandome Using a Reverse Immunology Approach[J]Midwifery,2015,30(10):1045.
[13]史先芳,何桂钧.慢性乙肝肝纤维化诊断相关小分子蛋白标志物的筛查[J].哈尔滨医科大学学报,2018,52(3):54-59.
[14]Latteri S,Catania VE,Malaguarnera G,et al.Carcinoembryonic Antigen Serum Levels in Nonmelanoma Skin Cancer[J].Biomedicines,2018,6(1):24.
[15]文君,李嘉,王春妍,等.血清异常凝血酶原复合物、甲胎蛋白、铁蛋白检测对HBV相关肝细胞癌的辅助诊断意义[J].临床肝胆病杂志,2017,33(9):1729-1733.
[2]庄辉.再论提高我国乙型肝炎治疗的可及性[J].肝脏,2016,24(6):401-402
[3]梁伟清.对乙肝表面抗原进行定量检测方法的研究[J].当代医药论丛,2018,16(6):49-50.
[4]吴丽萍.肿瘤标志物应用的注意事项[J].世界最新医学信息文摘,2015,15(35):105.
[5]耿亚军,赵鹏慧,梁威,等.抗病毒治疗对乙型肝炎病毒相关性原发性肝癌根治性术后肿瘤复发的影响[J].河北医学,2017,23(3):463-466.
[6]许侨东,颜永聪,黄拼搏,等.乙型肝炎病毒X蛋白在肝细胞癌中的病理作用及相关分子机制[J].实用医学杂志,2016,32(20):3448-3450.
[7]刘颖,朱以军,王月.金华地区慢性乙型肝炎患者HBV基因型及耐药基因位点突变类型分析[J].浙江医学,2017,39(14):1158-1161.
[8]郑积才,陈和敏.乙肝疫苗联合乙肝免疫球蛋白阻断乙肝母婴垂直传播的疗效及影响因素研究[J].中国全科医学,2017,20(S1):102-104.
[9]周其锋.淋巴瘤免疫化疗须防HBV再激活-《中国淋巴瘤合并HBV感染患者管理的专家共识》解读[J].医师在线,2017,7(25):23-24.
[10]石跃,朱丽影,于雷,等.HBV感染产妇应用替诺福韦酯期间哺乳婴儿安全性观察[J].中国肝脏病杂志(电子版),2018,10(2):43-48.
[11]朱复生,丁明霞,王明杰.乙肝疫苗联合乙肝免疫球蛋白阻断乙肝病毒垂直传播失败的相关危险因素分析[J].继续医学教育,2018,32(10):119-122.
[12]Hombrink P,Hassan C,Kester MG,et al.Identification of Biologica Relevant Minor Histocompatibility Antigens within the B-lymphocyteDerived HLA-Ligandome Using a Reverse Immunology Approach[J]Midwifery,2015,30(10):1045.
[13]史先芳,何桂钧.慢性乙肝肝纤维化诊断相关小分子蛋白标志物的筛查[J].哈尔滨医科大学学报,2018,52(3):54-59.
[14]Latteri S,Catania VE,Malaguarnera G,et al.Carcinoembryonic Antigen Serum Levels in Nonmelanoma Skin Cancer[J].Biomedicines,2018,6(1):24.
[15]文君,李嘉,王春妍,等.血清异常凝血酶原复合物、甲胎蛋白、铁蛋白检测对HBV相关肝细胞癌的辅助诊断意义[J].临床肝胆病杂志,2017,33(9):1729-1733.